TY - JOUR
T1 - Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation
AU - Brian Dalton, W.
AU - Helmenstine, Eric
AU - Walsh, Noel
AU - Gondek, Lukasz P.
AU - Kelkar, Dhanashree S.
AU - Read, Abigail
AU - Natrajan, Rachael
AU - Christenson, Eric S.
AU - Roman, Barbara
AU - Das, Samarjit
AU - Zhao, Liang
AU - Leone, Robert D.
AU - Shinn, Daniel
AU - Groginski, Taylor
AU - Madugundu, Anil K.
AU - Patil, Arun
AU - Zabransky, Daniel J.
AU - Medford, Arielle
AU - Lee, Justin
AU - Cole, Alex J.
AU - Rosen, Marc
AU - Thakar, Maya
AU - Ambinder, Alexander
AU - Donaldson, Joshua
AU - DeZern, Amy E.
AU - Cravero, Karen
AU - Chu, David
AU - Madero-Marroquin, Rafael
AU - Pandey, Akhilesh
AU - Hurley, Paula J.
AU - Lauring, Josh
AU - Park, Ben Ho
N1 - Publisher Copyright:
Copyright: © 2019, American Society for Clinical Investigation.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Cancer-associated mutations in the spliceosome gene SF3B1 create a neomorphic protein that produces aberrant mRNA splicing in hundreds of genes, but the ensuing biologic and therapeutic consequences of this missplicing are not well understood. Here we have provided evidence that aberrant splicing by mutant SF3B1 altered the transcriptome, proteome, and metabolome of human cells, leading to missplicing-associated downregulation of metabolic genes, decreased mitochondrial respiration, and suppression of the serine synthesis pathway. We also found that mutant SF3B1 induces vulnerability to deprivation of the nonessential amino acid serine, which was mediated by missplicing-associated downregulation of the serine synthesis pathway enzyme PHGDH. This vulnerability was manifest both in vitro and in vivo, as dietary restriction of serine and glycine in mice was able to inhibit the growth of SF3B1MUT xenografts. These findings describe a role for SF3B1 mutations in altered energy metabolism, and they offer a new therapeutic strategy against SF3B1MUT cancers.
AB - Cancer-associated mutations in the spliceosome gene SF3B1 create a neomorphic protein that produces aberrant mRNA splicing in hundreds of genes, but the ensuing biologic and therapeutic consequences of this missplicing are not well understood. Here we have provided evidence that aberrant splicing by mutant SF3B1 altered the transcriptome, proteome, and metabolome of human cells, leading to missplicing-associated downregulation of metabolic genes, decreased mitochondrial respiration, and suppression of the serine synthesis pathway. We also found that mutant SF3B1 induces vulnerability to deprivation of the nonessential amino acid serine, which was mediated by missplicing-associated downregulation of the serine synthesis pathway enzyme PHGDH. This vulnerability was manifest both in vitro and in vivo, as dietary restriction of serine and glycine in mice was able to inhibit the growth of SF3B1MUT xenografts. These findings describe a role for SF3B1 mutations in altered energy metabolism, and they offer a new therapeutic strategy against SF3B1MUT cancers.
UR - http://www.scopus.com/inward/record.url?scp=85074649290&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074649290&partnerID=8YFLogxK
U2 - 10.1172/JCI125022
DO - 10.1172/JCI125022
M3 - Article
C2 - 31393856
AN - SCOPUS:85074649290
SN - 0021-9738
VL - 129
SP - 4708
EP - 4723
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 11
ER -